MedTrace Logo

Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia

NCT02744690 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-08-01

No results posted yet for this study

Summary

This study is a randomized, double-masked trial to examine the response to trabeculectomy surgery. In this study, patients will be randomized to receive MMC via subconjunctival injection or topical sponge application.

Conditions

Interventions

DRUG

Mitomycin-C (MMC)

Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital

Sponsors & Collaborators

Principal Investigators

  • Jeremy D Keenan, MD, MPH · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-01
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • Ethiopia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02744690 on ClinicalTrials.gov